分化型甲状腺癌患者随访中131I显像与刺激后甲状腺球蛋白水平的评估:1420例患者的回顾性分析
该回顾性分析评估了1420例经甲状腺切除和放射性碘残余消融的分化型甲状腺癌患者,在规范化随访方案下诊断性全身131I显像(DxWBS)与刺激后甲状腺球蛋白(sTg)单独及联合应用的临床价值,以随访后4个月内实际接受进一步肿瘤治疗的记录指征为参考标准。结果显示sTg比DxWBS更能识别高危患者,两者均阴性时仅<2%患者后续需要治疗,RRA后12个月时该比例仅0.9%。作者认为当DxWBS阴性且sTg低于功能灵敏度(无甲状腺球蛋白抗体证据)时可完全省略DxWBS,其他情况DxWBS仍可能有正当理由。
要点
- sTg在识别需后续治疗的患者方面优于DxWBS。
- RRA后超过3个月是评估疗效最敏感的时间点,RRA后12个月时效应最强。
- DxWBS阴性且sTg低于功能灵敏度(无Tg抗体证据)时,后续需治疗比例<2%(12个月时仅0.9%)。
核心结论
- 一旦DxWBS阴性且sTg低于功能灵敏度(无甲状腺球蛋白抗体证据),在DTC的RRA后监测中完全省略DxWBS是合理的,因为该联合结果的患者(尤其是RRA后12个月)复发风险至多轻微。
- 在所有其他情况下,DxWBS可能仍有正当理由。
研究设计与样本
- 回顾性分析,纳入1420例经甲状腺切除和放射性碘残余消融、遵循明确治疗和标准化随访方案的分化型甲状腺癌患者。
- 在不同随访时间点分别及联合评估DxWBS与sTg,以随访后4个月内实际接受进一步肿瘤治疗(排除针对微小正常残余的放射性碘治疗)的记录指征为参考标准。
- 在可获取时比较DxWBS与治疗后WBS及SPECT(/CT);对诊断时<45岁且无远处转移的DTC患者进行亚组分析。
- 未评估颈部超声的诊断作用。
主要发现
- sTg比DxWBS更能识别处于风险中的患者。
- 评估疗效最敏感的时间点似乎是RRA后超过3个月。
- 当影像与实验室检查结果一致(均提示无残留疾病)时,仅<2%的患者未来需要治疗;该效应在RRA后12个月最强。
- 在RRA后12个月时,DxWBS阴性且sTg一致低于功能灵敏度的患者中仅0.9%此后需要治疗。
关键数值与推荐
- RRA后12个月时,DxWBS阴性且sTg一致低于功能灵敏度的患者中仅0.9%此后需要治疗。
- 影像与实验室结果一致提示无残留疾病时,仅<2%的患者未来需要治疗。
临床怎么用
- 作者认为,当DxWBS阴性且sTg低于功能灵敏度(无甲状腺球蛋白抗体证据)时,可完全省略DTC的RRA后监测中的DxWBS,尤其是RRA后12个月。
- 作者认为,在所有其他情况下DxWBS可能仍有正当理由。
局限性
- 未评估颈部超声的诊断作用。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To study the clinical yield of diagnostic whole body 131I scintigraphy (DxWBS) in the follow-up of differentiated thyroid carcinoma (DTC) patients in relation to stimulated thyroglobulin (sTg) in the initial post-ablation setting, as well as in the setting of repeated monitoring in course of further DTC follow-up. METHODS: Data of 1420 thyroidectomized and radioiodine remnant-ablated DTC patients following a well-defined therapy and standardized follow-up protocol were evaluated. DxWBS and sTg were evaluated separately and in combination for various follow-up time points. The factual administration of the recorded indication for further oncologic therapy (excluding radioiodine therapies given for minimal normal remnants) within the following 4 months after follow-up served as the standard of reference. Furthermore, DxWBS was compared to post therapy WBS and SPECT(/CT) if available. Subgroup analysis was carried out for DTC patients < 45 years old at diagnosis without distant metastasis. The diagnostic impact of cervical ultrasound was not assessed. RESULTS: sTg can identify the patients at risk better than DxWBS. Furthermore, the most sensitive time point to assess response appears to be a time point beyond 3 months after RRA. When information received from both imaging and laboratory measurements are concordant, i.e. both construe absence of remaining disease, only a small fraction of patients (<2%) required treatment in the future. The strongest effect was observed 12 months after RRA. Only 0.9% of the negative DxWBS patients with concordant sTg below the functional sensitivity at this time point required treatment thereafter. CONCLUSION: A complete omission of DxWBS in the post-RRA surveillance of DTC is justified once DxWBS is negative and sTg is below the functional sensitivity (with no evidence of thyroglobulin antibodies), as patients showing this combination of test results (especially 12 months after RRA) show an at worst marginal risk of recurrence. In all other cases DxWBS may still be justified.
引用
- Gonzalez Carvalho JM, Görlich D, Schober O, et al. Evaluation of 131I scintigraphy and stimulated thyroglobulin levels in the follow up of patients with DTC: a retrospective analysis of 1420 patients. Eur J Nucl Med Mol Imaging. 2016. PMID: 27909769. doi:10.1007/s00259-016-3581-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。